Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash & Equivalents (2021 - 2025)

Barinthus Biotherapeutics' Cash & Equivalents history spans 5 years, with the latest figure at $74.3 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 30.0% year-over-year to $74.3 million; the TTM value through Sep 2025 reached $74.3 million, down 30.0%, while the annual FY2023 figure was $142.1 million, 26.9% down from the prior year.
  • Cash & Equivalents reached $74.3 million in Q3 2025 per BRNS's latest filing, down from $86.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $243.6 million in Q2 2021 to a low of $74.3 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $162.0 million, with a median of $166.7 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: rose 28.64% in 2022, then crashed 33.81% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $214.1 million in 2021, then fell by 9.19% to $194.4 million in 2022, then dropped by 26.9% to $142.1 million in 2023, then decreased by 25.33% to $106.1 million in 2024, then dropped by 30.0% to $74.3 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Cash & Equivalents are $74.3 million (Q3 2025), $86.3 million (Q2 2025), and $99.1 million (Q1 2025).